Finance

Roʻyxatlar
Nega 524494 tushdi 3,51%?
Batafsil oʻrganish
524494:BOM
IPCA Laboratories Ltd
1 845,00 ₹
-3,51%
(-67,20) 1K
16-okt, 15:30:00 (GMT+5:30)  ·   INR
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
524494 tikeri uchun statistika yaratilmoqda...
Ochish
1 913,95 ₹
Yuqori
1 913,95 ₹
Past
1 812,60 ₹
Bozor kapitali
468,21 mlrd
Oʻrtacha hajm
27,90 ming
Hajmi
12,00 ming
Dividend
0,33%
Choraklik dividendlar
1,50 ₹
Eks-dividend sanasi
7-avg, 2026
P/E koeffitsiyenti
35,74
52 haftalik eng yuqori
2 039,30 ₹
52 haftalik eng past
1 252,95 ₹
Aksiya boʻyicha daromad
51,63 ₹
Muomaladagi aksiyalar
126,35 mln
Xodimlar soni
17 ming
Ochish
1 913,95 ₹
Yuqori
1 913,95 ₹
Past
1 812,60 ₹
Bozor kapitali
468,21 mlrd
Oʻrtacha hajm
27,90 ming
Hajmi
12,00 ming
Dividend
0,33%
Choraklik dividendlar
1,50 ₹
Eks-dividend sanasi
7-avg, 2026
P/E koeffitsiyenti
35,74
52 haftalik eng yuqori
2 039,30 ₹
52 haftalik eng past
1 252,95 ₹
Aksiya boʻyicha daromad
51,63 ₹
Muomaladagi aksiyalar
126,35 mln
Xodimlar soni
17 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries. Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
IPCA Laboratories Ltd haqida
CEO-
Xodimlar soni17,2 ming
Asos solingan19-okt, 1949
Bosh ofislar-
Sektor-
Veb-saytipca.com
Avvalgi hisobotlarBarcha qiymatlar – INR
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – INR
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
25,56 mlrd
23,92 mlrd
23,89 mlrd
27,88 mlrd
Sotilgan mahsulotning tannarxi
7,82 mlrd
6,58 mlrd
10,31 mlrd
7,97 mlrd
Daromad narxi
7,82 mlrd
6,58 mlrd
10,31 mlrd
7,97 mlrd
Tadqiqot va ishlanmalarga xarajatlar
-
-
-
-
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
5,38 mlrd
5,46 mlrd
5,54 mlrd
6,02 mlrd
Operatsion xarajatlar
13,33 mlrd
13,09 mlrd
9,17 mlrd
14,32 mlrd
Jami operatsion xarajatlar
21,15 mlrd
19,67 mlrd
19,48 mlrd
22,29 mlrd
Operatsion daromad
4,42 mlrd
4,26 mlrd
4,41 mlrd
5,59 mlrd
Boshqa nooperatsion daromad
278,60 mln
201,90 mln
-680,30 mln
252,60 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
3,89 mlrd
4,46 mlrd
4,02 mlrd
5,74 mlrd
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
4,47 mlrd
4,28 mlrd
3,62 mlrd
5,74 mlrd
Daromad soligʻi boʻyicha xarajat
1,08 mlrd
819,30 mln
950,50 mln
1,49 mlrd
Amaldagi soliq stavkasi
27,81%
18,39%
23,66%
26,03%
Boshqa operatsion xarajatlar
6,92 mlrd
6,55 mlrd
2,56 mlrd
7,20 mlrd
Sof foyda
2,83 mlrd
3,26 mlrd
2,99 mlrd
4,02 mlrd
Sof foyda marjasi
11,05%
13,64%
12,52%
14,41%
Har bir aksiya foydasi
12,35
12,09
13,31
15,84
Foizlar va investitsiyalardan olingan daromadlar
-
-
317,20 mln
-
Foizlarni toʻlash xarajatlari
-196,10 mln
-176,20 mln
-199,90 mln
-118,80 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
-196,10 mln
-176,20 mln
117,30 mln
-118,80 mln
Amortizatsiya ajratmalari
1,03 mlrd
1,08 mlrd
1,04 mlrd
1,11 mlrd
EBITDA
5,43 mlrd
5,18 mlrd
5,37 mlrd
6,55 mlrd
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari